Berlin
13.08.25 | 19:35
15,990 Euro
-2,68 % -0,440
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.07. | XVIVO Perfusion AB: Delay in CE Approval for XVIVO's Perfusion Solution for Heart Preservation | 349 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / July 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV). The XVIVO Heart Assist Transport and the XVIVO Heart Assist Transport Perfusion Set have received... ► Artikel lesen | |
| 22.07. | Xvivo enrolls first patient in Heart Assist Transport device study | 1 | MassDevice | ||
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 21.07. | XVIVO Perfusion AB: First Patient Enrolled in US PRESERVE CAP Study for XVIVO Heart Assist Transport Device | 231 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 21, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, XVIVO announces that the first patient has been enrolled as part of the Continued Access... ► Artikel lesen | |
| 11.07. | XVivo Q2 2025: Umsatzrückgang lässt Aktie einbrechen | 8 | Investing.com Deutsch | ||
| 11.07. | XVIVO Perfusion AB: Interim Report January-June 2025 | 237 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 11, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)A quarter showing a mixed pictureSecond quarter 2025 (Apr-Jun)• Net sales amounted to SEK 178.3 million... ► Artikel lesen | |
| 11.07. | Marktgegenwind bremst XVIVO: Organisches Wachstum im zweiten Quartal um 11 % rückläufig | 4 | Investing.com Deutsch | ||
| 11.07. | XVIVO Q2 2025 slides reveal -11% organic growth amid market headwinds | 2 | Investing.com | ||
| 10.07. | XVIVO Perfusion AB: Conference Call on Interim Report April-June 2025 | 292 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 10, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2025. The... ► Artikel lesen | |
| 13.06. | XVIVO Perfusion AB: XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market | 252 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA)... ► Artikel lesen | |
| 29.04. | XVIVO Perfusion AB: XVIVO Presents 12-Month Follow-Up Results from European Multicenter Heart Transplantation Trial at ISHLT in Boston | 297 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 29, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - The 12-month follow-up results from XVIVO's European multicenter heart trial, NIHP2019, was presented... ► Artikel lesen | |
| 25.04. | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 352 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04. | XVIVO Perfusion AB: Interim Report January-March 2025 | 232 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2025 (Jan-Mar)Net sales increased to SEK 218.6 million (186.0), corresponding to growth... ► Artikel lesen | |
| 15.04. | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2025 | 375 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.... ► Artikel lesen | |
| 02.04. | XVIVO Perfusion AB: Annual Report 2024 | 310 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 2, 2025 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)Today XVIVO Perfusion AB (publ) publish the Annual Report for 2024. The Annual Report is attached... ► Artikel lesen | |
| 20.03. | Notice to Attend the Annual General Meeting in XVIVO Perfusion AB | 325 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / March 20, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice... ► Artikel lesen | |
| 28.01. | XVIVO Perfusion AB: Year-End Report 2024 | 269 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / January 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2024 (October 1 - December 31)• Net sales amounted to SEK 227.6 million (155.7), corresponding... ► Artikel lesen | |
| 13.01. | XVIVO Perfusion AB: Conference Call on Year-End Report 2024 | 404 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / January 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report... ► Artikel lesen | |
| 26.11.24 | XVIVO Perfusion AB: Enrollment Completed Five Months Early in the US Clinical Trial Evaluating XVIVOs Heart Preservation Technology | 411 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / November 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO's innovative heart technology is currently under investigation in the US clinical trial "PRESERVE:... ► Artikel lesen | |
| 14.11.24 | XVIVO Perfusion AB: XVIVO Perfusion Appoints Lena Hagman as Deputy CEO | 293 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / November 14, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The Board of Directors of XVIVO Perfusion AB (publ) ("XVIVO") has today appointed Lena Hagman... ► Artikel lesen | |
| 24.10.24 | XVIVO Perfusion AB: Interim Report January-September 2024 | 327 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / October 24, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Third quarter 2024 (July 1 - September 30)• Net sales amounted to SEK 198.5 million (146.6), corresponding... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 19,530 | -64,81 % | DAX-Check LIVE: Bechtle, Deutz, Eckert & Ziegler, Heidelberg Materials, Jungheinrich, Munich Re & Co | Neue Hoffnungen auf einen baldigen Waffenstillstand im Ukraine-Krieg haben gestern am deutschen Aktienmarkt für eine freundliche Stimmung gesorgt. Der DAX übersprang die runde Marke von 24.000 Punkten... ► Artikel lesen | |
| INTUITIVE SURGICAL | 412,05 | -0,10 % | ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue? | ||
| UNITEDHEALTH | 232,20 | -0,09 % | 3 Aktien mit Potenzial? BYD, UnitedHealth, FedEx im Check | Die US-Börsen haben sichtlich von den besser als erwartet ausgefallenen Inflationsdaten profitiert. Samir Boyardan und Andreas Wolf von HeavytraderZ analysieren die Lage und werfen darüber hinaus einen... ► Artikel lesen | |
| RHOEN-KLINIKUM | 11,800 | -0,84 % | EQS-News: RHÖN-KLINIKUM Aktiengesellschaft: RHÖN-KLINIKUM AG schließt mit solidem Ergebnis erstes Halbjahr 2025 ab | EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Schlagwort(e): Halbjahresergebnis/Sonstiges
RHÖN-KLINIKUM AG schließt mit solidem Ergebnis erstes Halbjahr 2025 ab
07.08.2025... ► Artikel lesen | |
| HIMS & HERS HEALTH | 41,340 | +0,07 % | Nach dem Earnings-Crash: Hims & Hers: Die Verluste hören einfach nicht auf! | © Foto: Thomas Fuller - SOPA Images via ZUMA Press WireDie Anteile der wachstumsstarken US-Online-Apotheke Hims & Hers befinden sich nach dem jüngsten Quartalsbericht im Sinkflug. Am Dienstag gab es... ► Artikel lesen | |
| BICO GROUP | 3,170 | -0,06 % | Schock-News für Bico Group Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| M1 KLINIKEN | 13,820 | -1,99 % | Dividendenbekanntmachungen (17.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) CRANSWICK PLC GB0002318888 0,76 GBP 0,8762 EUR DIME COMMUNITY BANCSHARES INC US25432X1028 0,25 USD 0,2148 EUR EOG RESOURCES INC US26875P1012 0... ► Artikel lesen | |
| BAXTER | 20,425 | -0,87 % | ROUNDUP: Baxter International Trims FY25 Outlook | DEERFIELD (dpa-AFX) - While reporting financial results for the second quarter on Thursday, health care company Baxter International, Inc. (BAX) initiated its earnings, adjusted earnings and... ► Artikel lesen | |
| LIFEWARD | 0,709 | 0,00 % | Lifeward Ltd.: Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| COOPER COMPANIES | 60,50 | -4,72 % | Cooper Companies-Aktie heute gut behauptet: Aktienwert steigt (63,2956 €) | Die Aktie von Cooper Companies notiert heute ein wenig fester. Der jüngste Kurs betrug 74,04 US-Dollar. Freuen können sich gegenwärtig die Aktionäre von Cooper Companies: Das Papier weist aktuell eine... ► Artikel lesen | |
| JD HEALTH | 6,150 | +0,82 % | HSI Up 643 pts; HSTI Up 191 pts; BABA Up over 6%; TENCENT Up over 4%; MEITUAN Up over 4%; TENCENT, WH GROUP, HANSOH PHARMA, JD HEALTH, ZIJIN MINING Hit New Highs; Market Turnover Rises | ||
| SURGICAL SCIENCE SWEDEN | 9,000 | -0,55 % | Surgical Science Sweden AB: Sales in the second quarter were weak, which together with large currency effects weighed on the result | According to the preliminary reporting, Surgical Science's sales for the second quarter amounted to approximately SEK 209 million, a decrease of 2% compared to the second quarter of 2024. For the various... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 3,160 | -3,07 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results | [212Pb]VMT-a-NET study update presented at the 2025 ASCO Annual Meeting, based on updated interim results from a Phase 1/2a study in neuroendocrine tumors. As of the April 30, 2025 data cut-off date:... ► Artikel lesen | |
| COMMUNITY HEALTH SYSTEMS | 2,160 | +3,85 % | COMMUNITY HEALTH SYSTEMS INC - 8-K, Current Report | ||
| SOLENO THERAPEUTICS | 70,25 | +1,30 % | Stifel hebt Kursziel für Soleno Therapeutics nach starkem Produktstart auf 118 $ |
Das Unternehmen XVIVO PERFUSION AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 15,990 Euro und damit -2,68 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.